BioXcel Therapeutics (BTAI) Share-based Compensation (2017 - 2025)

BioXcel Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.8 million for Q4 2025.

• On a quarterly basis, Share-based Compensation rose 1481.91% year-over-year to $2.8 million in Q4 2025; TTM through Mar 2026 was $4.9 million, a 68.34% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, down 64.02% from the prior year.
• Share-based Compensation improved to $2.8 million in Q4 2025 per BTAI's latest filing, from $581000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $18.6 million in Q4 2023 and bottomed at -$199000.0 in Q4 2024.
• The 5-year median for Share-based Compensation is $3.6 million (2022), against an average of $3.7 million.
• Biggest YoY gain for Share-based Compensation was 12614.81% in 2024; the steepest drop was 101.07% in 2024.
• Year by year, Share-based Compensation stood at $2.2 million in 2021, then surged by 103.35% to $4.5 million in 2022, then soared by 308.78% to $18.6 million in 2023, then slumped by 101.07% to -$199000.0 in 2024, then jumped by 1481.91% to $2.8 million in 2025.
• Per Business Quant, the three latest BTAI Share-based Compensation figures stand at $2.8 million (Q4 2025), $581000.0 (Q3 2025), and $1.6 million (Q2 2025).